Overview

Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma

Status:
Completed
Trial end date:
2018-07-09
Target enrollment:
Participant gender:
Summary
A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations (with chemotherapy or AZD5069) in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Durvalumab
Gemcitabine
Paclitaxel